{\rtf1 \ansi 
{\colortbl;
\red0\green0\blue0;
\red255\green255\blue255;
\red255\green0\blue0;
\red0\green255\blue0;
\red0\green0\blue255;
\red0\green255\blue255;
\red255\green0\blue255;
\red255\green255\blue0;
\red0\green0\blue128;
\red0\green128\blue128;
\red0\green128\blue0;
\red128\green0\blue128;
\red128\green0\blue0;
\red128\green128\blue0;
\red128\green128\blue128;
\red192\green192\blue192;
\red170\green170\blue170;
\red85\green85\blue85;
\red107\green107\blue106;
\red14\green86\blue140;
\red33\green33\blue33;
\red37\green37\blue37;
\red255\green255\blue102;
\red249\green250\blue251;
\red204\green204\blue204;
\red228\green231\blue232;
\red119\green119\blue119;
\red238\green238\blue238;
\red20\green93\blue164;
\red246\green246\blue246;
\red80\green80\blue80;
\red51\green51\blue51;
\red181\green79\blue104;
\red151\green151\blue151;
\red0\green114\blue54;
\red254\green254\blue0;
\red106\green144\blue39;
\red56\green124\blue43;
\red233\green233\blue233;
\red21\green137\blue21;
\red232\green233\blue232;
\red249\green249\blue249;
\red255\green248\blue96;
\red112\green112\blue112;
\red214\green9\blue9;
\red247\green247\blue247;
\red255\green194\blue211;
\red203\green203\blue203;
\red245\green245\blue245;
\red187\green187\blue187;
\red118\green118\blue118;
\red240\green240\blue240;
\red105\green105\blue105;
\red227\green227\blue227;
\red242\green242\blue242;
\red239\green122\blue2;
\red190\green190\blue252;
\red236\green236\blue236;
\red255\green255\blue204;
\red255\green204\blue0;
\red229\green243\blue255;
\red179\green218\blue255;
\red185\green185\blue185;
\red218\green218\blue218;
\red223\green223\blue223;
\red239\green239\blue239;
\red255\green255\blue198;
\red188\green41\blue30;
\red190\green237\blue228;
\red255\green255\blue174;
\red102\green0\blue102;
\red61\green61\blue61;
\red214\green214\blue214;
\red102\green102\blue102;
\red240\green248\blue255;
\red127\green127\blue127;
\red183\green242\blue206;
\red204\green255\blue255;
\red182\green231\blue243;
\red71\green120\blue194;
\red153\green255\blue102;
}
{\fonttbl {
\f0 Arial;}{
\f1 Symbol;}{
\f2 Times New Roman;}{
\f3 georgia;}{
\f4 sans-serif;}{
\f5 Source Sans Pro;}{
\f6 Courier New;}{
\f7 serif;}
}
{\*\generator Apache XML Graphics RTF Library;}
\fet0 \ftnbj 
{\*\listtable
{\list\listtemplateid1313194232\listsimple{\listlevel\leveljc\levelfollow0\levelspace0\levelindent0{\leveltext\'01\u160\'3f}{\levelnumbers}}{\listname ;}\listid-1991539624}
}
{\*\listoverridetable
{\*\listoverride{\listid-1991539624\listoverridecount0\ls1}}
}
\paperw12240 \paperh15840 \margt1080 \margb1080 \margl1080 \margr1080 \headery720 \footery720 \itap0 \cols2 
\sectd {\header {
{\trowd \ltrrow \trleft0 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrl \trql \clvertalb \clwWidth9380 \cellx9380 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrr \trql \clwWidth700 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
{\b1 \cf18 \f0 \i0 \fs18 
{\b1 \cf18 \f0 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Cleveland Clinic Foundation v. True Health Diagnostics LLC, 859 F.3d 1352 (2017)
}
}
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
}\b0 \cf1 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs18 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 
}\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
123 U.S.P.Q.2d 1081
}
}\b0 \cf1 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs18 \li0 \sa0 \sb0 \intbl \cell \row }}\par }{\footer {
{\trowd \lastrow \trleft0 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrl \trql \clvertalb \clwWidth9300 \cellx9300 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrr \trql \clwWidth700 \cellx10000 
\intbl 
{\b0 \cf17 \f0 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 
}
{\*\shppict {\pict \pngblip \picw78 \pich10 \picwgoal1170 \pichgoal150 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}}
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
}
}\b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs20 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf17 \f0 \ri0 \i0 \fs20 \li0 
{\b0 \i0 \ul0 \fs20 \f0 \chpgn }
}\qr \b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \fs20 \li0 \intbl \cell \row }}\par }
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_document_31}{\*\bkmkend co_document_31}
{\b0 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart Ic994c70052ad11e7a3f3a229dca6c9c6_Target}{\*\bkmkend Ic994c70052ad11e7a3f3a229dca6c9c6_Target}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeKC_31}{\*\bkmkend co_readingModeKC_31}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeCitatorFlag_31}{\*\bkmkend co_readingModeCitatorFlag_31}
{\b0 \cf1 \f2 \i0 \fs16 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/RelatedInformation/Flag?documentGuid=Ic994c70052ad11e7a3f3a229dca6c9c6&transitionType=Document&originationContext=docHeaderFlag&Rank=0&rs=cblt1.0&vr=3.0&contextData=(sc.Search)" }{\fldrslt 
{\*\shppict {\pict \pngblip \picw16 \pich16 \picwgoal255 \pichgoal255 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}}}}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
KeyCite Yellow Flag - Negative Treatment
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeNegativeTreatment_31}{\*\bkmkend co_readingModeNegativeTreatment_31}
{\b0 \cf1 \f2 \i0 \fs16 {\fi-360 \li {\*\pn \pnlvlblt \ilvl0 \ls1 \pnindent0 \pnf1 {\f2 \pntxtb \u160\'3f}}{\listtext \b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 \u160\'3f\tab }\ls1 {\pntext }
{\pard }\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
Distinguished by 
}
}
{\field {\*\fldinst HYPERLINK "https://www.westlaw.com/Document/I5e479860d35611ea9701a3ff415cad6f/View/FullText.html?navigationPath=RelatedInfo%2Fv4%2Fkeycite%2Fnav%2F%3Fguid%3DI5e479860d35611ea9701a3ff415cad6f%26ss%3D2041877586%26ds%3D2051564273%26origDocGuid%3DIc994c70052ad11e7a3f3a229dca6c9c6&listSource=RelatedInfo&list=NegativeCitingReferences&rank=0&ppcid=5cd94d6206c547a5b78554264af3d4d5&originationContext=docHeader&transitionType=NegativeTreatment&contextData=%28sc.Search%29&VR=3.0&RS=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
XY, LLC v. Trans Ova Genetics, LC
}
{\b0 \cf20 \f2 \i0 \fs16 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
, 
}
}}}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
Fed.Cir.(Colo.), 
}
}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
July 31, 2020
\par {\pntext }
}
}
}
}
}
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
859 F.3d 1352
\par 
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
United States Court of Appeals, Federal Circuit.
\par 
}
}
}
{\b0 \qc \cf22 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf22 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf22 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf22 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb240 
The CLEVELAND CLINIC FOUNDATION, Cleveland Heartlab, Inc., Plaintiffs\u8211\'3fAppellants
\par 
}
}
{\b0 \qc \cf22 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf22 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
v.
\par 
}
}
{\b0 \qc \cf22 \f3 \ri120 \i0 \fs24 \li120 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Search/Results.html?query=advanced%3a+OAID(5046704989)&saveJuris=False&contentType=BUSINESS-INVESTIGATOR&startIndex=1&contextData=(sc.Default)&categoryPageUrl=Home%2fCompanyInvestigator&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem" }{\fldrslt 
{\b0 \cf20 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
TRUE HEALTH DIAGNOSTICS LLC
}}}
{\b0 \cf22 \f3 \ul0 \strike0 \i0 \fs24 \sa240 \sb0 
, Defendant\u8211\'3fAppellee
\par 
}
}
}
}
{\b0 \qc \cf1 \f2 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
2016-1766
\par 
}
}
}
{\b0 \cf1 \f3 \i0 \fs20 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
|
\par 
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
Decided: June 16, 2017
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_synopsis_31}{\*\bkmkend co_synopsis_31}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
Synopsis
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Background:
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Owner of patents claiming methods for testing for myeloperoxidase (MPO) in a bodily sample and patent claiming method for treating a patient that had cardiovascular disease brought infringement action. The United States District Court for the Northern District of Ohio, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037655832&pubNum=0004031&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PD&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
No. 1:15\u8211\'3fcv\u8211\'3f02331\u8211\'3fPAG
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0152496001&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Patricia A. Gaughan
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, J., 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038337569&pubNum=0000999&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
2016 WL 705244
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, found that claims of testing patents were not directed to patent-eligible subject matter and that patent owner failed to state a claim of contributory or induced infringement of fourth patent. Patent owner appealed.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Holdings:
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Court of Appeals, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0156955701&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Reyna
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
, Circuit Judge, held that:
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
patent claims were directed to patent-ineligible law of nature;
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
claims did not result in an inventive concept that transformed natural phenomena of MPO being associated with cardiovascular risk into a patentable invention;
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
patent owner failed to state claim for contributory infringement; and
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
patent owner failed to state claim against competitor for induced infringement.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Affirmed.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1354_31}{\*\bkmkend co_pp_sp_506_1354_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1354
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 Appeal from the United States District Court for the Northern District of Ohio in No. 1:15\u8211\'3fcv\u8211\'3f02331\u8211\'3fPAG, Judge Patricia A. Gaughan.
\par 
}
}
}
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_attorneysAndLawFirms_31}{\*\bkmkend co_attorneysAndLawFirms_31}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
Attorneys and Law Firms
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1355_31}{\*\bkmkend co_pp_sp_506_1355_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1355
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0219436401&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Lawrence D. Rosenberg
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0177049701&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Jones Day
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Washington, DC, argued for plaintiffs-appellants. Also represented by 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0318310601&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Susan M. Gerber
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Cleveland, OH.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0337247201&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Adam Louis Marchuk
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Perkins Coie LLP, Chicago, IL, argued for defendant-appellee. Also represented by 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0321413601&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Michael Robert Osterhoff
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Mark T. Smith, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0474361801&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Caroline Ayres Teichner
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0175349501&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Dan L. Bagatell
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Hanover, NH.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Before 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0225327201&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Lourie
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0156955701&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Reyna
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0126887301&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Wallach
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Circuit Judges.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_opinion_31}{\*\bkmkend co_opinion_31}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
Opinion
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I6129d4a2c12a11eab3329bf22d04b}{\*\bkmkend co_anchor_I6129d4a2c12a11eab3329bf22d04b}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0156955701&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Reyna
}}}
\sa200 
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
, Circuit Judge.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I6143c542c12a11eab3329bf22d04b}{\*\bkmkend co_anchor_I6143c542c12a11eab3329bf22d04b}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Cleveland Clinic Foundation and Cleveland Heartlab, Inc. accused True Health Diagnostics LLC of infringement of three patents that claim methods for testing for myeloperoxidase in a bodily sample and a fourth patent that claims a method for treating a patient that has 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The United States District Court for the Northern District of Ohio found that the asserted claims of the three testing patents are not directed to patent-eligible subject matter and that Cleveland Clinic failed to state a claim of contributory or induced infringement of the fourth patent. For the reasons explained below, we affirm.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I61446181c12a11eab3329bf22d04b}{\*\bkmkend co_anchor_I61446181c12a11eab3329bf22d04b}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
Background
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In 2003, researchers at the Cleveland Clinic Foundation developed methods for detecting the risk of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in a patient. When an artery is damaged or inflamed, the body releases the enzyme myeloperoxidase, or MPO, in response. MPO is an early symptom of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and it can thus serve as an indicator of a patient\u8217\'3fs risk of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The prior art taught that MPO could be detected in an 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib7c7ef86475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
atherosclerotic plaque
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or lesion that required a surgically invasive method. Another prior art method 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
indirectly
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 detected for MPO in blood. Yet another known method could detect MPO in blood but yielded results that were not predictive of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The inventors here purportedly discovered how to \u8220\'3fsee\u8221\'3f MPO in blood and correlate that to the risk of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The patents disclose methods for detecting MPO and correlating the results to cardiovascular risk.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00012041877586_ID0ER2AG_31}{\*\bkmkend co_fnRef_B00012041877586_ID0ER2AG_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00012041877586_31" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
1
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The patents disclose that \u8220\'3f[m]yeloperoxidase activity may be determined by any of a variety of standard methods known in the art.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
E.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, J.A. 39 at col. 8 ll. 32\u8211\'3f33. These methods include colorimetric-based assay, flow 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic8ad5894475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cytometry
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic7562c94475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
enzyme-linked immunosorbent assay
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fELISA\u8221\'3f). Additionally, the patents disclose MPO detection kits modified from commercially available kits \u8220\'3fby including, for example, different cut-offs, different sensitivities at particular cut-offs, as well as instructions or other printed material for characterizing risk based upon the outcome of the assay.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
E.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, J.A. 38 at col. 6 ll. 21\u8211\'3f24.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In addition to ways to \u8220\'3fsee\u8221\'3f MPO, the inventors developed a way to correlate MPO with risk of developing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. To do this, the inventors compiled MPO data from a population to create a \u8220\'3fpredetermined\u8221\'3f or \u8220\'3fcontrol\u8221\'3f value. Then, using statistical methods, the inventors analyzed the data based on whether the person was \u8220\'3fapparently healthy\u8221\'3f or had some 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
E.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, J.A. 45 at col. 20 ll. 32\u8211\'3f43. Diagnosers could then use this data to determine whether a 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1356_31}{\*\bkmkend co_pp_sp_506_1356_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1356
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 patient presents a risk of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
If the level of the present risk predictor in the test subject\u8217\'3fs bodily sample is greater than the predetermined value or range of predetermined values, the test subject is at greater risk of developing or having [
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
] than individuals with levels comparable to or below the predetermined value or predetermined range of values.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
J.A. 46 at col. 21 ll. 37\u8211\'3f42.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims methods for characterizing a test subject\u8217\'3fs risk for 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 by determining levels of MPO in a bodily sample and comparing that with the MPO levels in persons not having 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The dependent claims limit the way MPO is detected and how the MPO values in the control subjects are evaluated. The district court analyzed claims 11, 14, and 15, which provide:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
11. A method of assessing a test subject\u8217\'3fs risk of having 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib080618a475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
atherosclerotic cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, comprising
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
comparing levels of myeloperoxidase in a bodily sample from the test subject with levels of myeloperoxidase in comparable bodily samples from control subjects diagnosed as not having the disease, said bodily sample being blood, serum, plasma, blood 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iadf4fbaa475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
leukocytes
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 selected from the group consisting of neutrophils, monocytes, sub-populations of neutrophils, and sub-populations of monocytes, or any combination thereo[f];
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
wherein the levels of myeloperoxidase in the bodily from the test subject relative to the levels of [m]yeloperoxidase in the comparable bodily samples from control subjects is indicative of the extent of the test subject\u8217\'3fs risk of having 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib080618a475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
atherosclerotic cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
J.A. 50 at col. 30 ll. 48\u8211\'3f62.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
14. A method of assessing a test subject\u8217\'3fs risk of developing a complication of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib080618a475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
atherosclerotic cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 comprising:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
determining levels of myeloperoxidase (MPO) activity, myeloperoxidase (MPO) mass, or both in a bodily sample of the test subject, said bodily sample being blood, serum, plasma, blood 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iadf4fbaa475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
leukocytes
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 selected from the group consisting of neutrophils and monocytes, or any combination thereof;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
wherein elevated levels of MPO activity or MPO mass or both in the test subject\u8217\'3fs bodily sample as compared to levels of MPO activity, MPO mass, or both, respectively in comparable bodily samples obtained from control subjects diagnosed as not having the disease indicates that the test subject is at risk of developing a complication of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib080618a475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
atherosclerotic cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
J.A. 51 at col. 31 ll. 8\u8211\'3f23.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
15. The method of claim 14, wherein the test subject\u8217\'3fs risk of developing a complication of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib080618a475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
atherosclerotic cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 is determined by comparing levels of my[elo]peroxidase mass in the test subject\u8217\'3fs bodily sample to levels of myeloperoxidase mass in comparable samples obtained from the control subjects.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
J.A. 51 at col. 31 ll. 24\u8211\'3f29.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2017572769&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=I86f818b8c15511ddbc7bf97f340af743&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f286 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2029620427&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=Ib76976f05b5b11e2b7b9d48fe009f569&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f581 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 further claim ways of detecting MPO. The dependent claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2017572769&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=I86f818b8c15511ddbc7bf97f340af743&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f286 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 limit MPO detection by flow 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic8ad5894475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cytometry
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and further require detection of another compound, troponin. Other dependent claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2017572769&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=I86f818b8c15511ddbc7bf97f340af743&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f286 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2029620427&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=Ib76976f05b5b11e2b7b9d48fe009f569&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f581 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 require detection of MPO byproducts. The district court analyzed claims 21 and 22 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2017572769&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=I86f818b8c15511ddbc7bf97f340af743&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f286 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and claim 5 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2029620427&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=Ib76976f05b5b11e2b7b9d48fe009f569&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f581 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which provide:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
21. A method of assessing the risk of requiring medical intervention in a patient who is presenting with chest pain, comprising
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1357_31}{\*\bkmkend co_pp_sp_506_1357_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1357
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 characterizing the levels of myeloperoxidase activity, myeloperoxidase mass, or both, respectively in the bodily sample from the human patient, wherein said bodily sample is blood or a blood derivative,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
wherein a patient whose levels of myeloperoxidase activity, myeloperoxidase mass, or both is characterized as being elevated in comparison to levels of myeloperoxidase activity, myeloperoxidase mass or both in a comparable bodily samples obtained from individuals in a control population is at risk of requiring medical intervention to prevent the occurrence of an adverse cardiac event within the next six months.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
J.A. 71 at col. 23 l. 45\u8211\'3fcol. 24 l. 10.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
22. A method of determining whether a patient who presents with chest pain is at risk of requiring medical intervention to prevent an adverse cardiac event within the next six months comprising:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
comparing the level of a risk predictor in a bodily sample from the subject with a value that is based on the level of said risk predictor in comparable samples from a control population, wherein said risk predictor is myeloperoxidase activity, myeloperoxidase mass, a myeloperoxidase-generated oxidation product, or any combination thereof, and wherein said bodily sample is blood, serum, plasma, or urine,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
wherein a subject whose bodily sample contains elevated levels of said risk predictor as compared to the control value is at risk of requiring medical intervention to prevent an adverse cardiac event within 6 months of presenting with chest pain, and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
wherein the difference between the level of the risk predictor in the patient\u8217\'3fs bodily sample and the level of the risk predictor in a comparable bodily sample from the control population establishes the extent of the risk to the subject of requiring medical intervention to prevent an adverse cardiac event within the next six months.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
J.A. 71 at col. 24 ll. 11\u8211\'3f33.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
5. A method of determining whether a patient who presents with chest pain is at risk of requiring medical intervention to prevent an adverse cardiac event within the next six months comprising:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
determining the level of risk predictor in a bodily sample from the subject, wherein said risk predictor is myeloperoxidase activity, myeloperoxidase mass, a myeloperoxidase (MPO)-generated oxidation product or any combination thereof,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
wherein said bodily sample is blood, serum, plasma or urine,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
wherein said myeloperoxidase-generated oxidation product is nitrotyrosine or a myeloperoxidase-generated lipid peroxidation product selected from [list of products] or any combination thereof, and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
comparing the level of said risk predictor in the bodily sample of the patient to the level of said risk predictor in comparable samples obtained from a control population,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
wherein a subject whose bodily sample contains elevated levels of said risk predictor as compared to the control value is at risk of requiring medical intervention to prevent an adverse cardiac event within 6 months of presenting with chest pain.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
J.A. 86 at col. 20 ll. 12\u8211\'3f50.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f260 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 builds on these patents and requires administration of a lipid lowering drug to a patient at risk of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f260 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 recites:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
1. A method for administering a lipid lowering agent to a human patient based on elevated levels of myeloperoxidase (MPO) mass and/or activity comprising:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1358_31}{\*\bkmkend co_pp_sp_506_1358_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1358
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (a) performing an 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic7562c94475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
enzyme linked immunosorbent assay
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 (ELISA) comprising contacting a serum or plasma sample with an anti-MPO antibody and a peroxidase activity assay to determine MPO activity in the serum or plasma sample;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
(b) selecting a patient who has elevated levels of MPO mass and/or activity compared to levels of MPO mass and/or activity in apparently healthy control subjects; and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
(c) administering a lipid lowering agent to the selected human patient.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
J.A. 117 at col. 30 ll. 10\u8211\'3f23.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
True Health is a diagnostic laboratory. It purchased the assets of Health Diagnostics Lab, which had contracted with the Cleveland Clinic to perform MPO testing. Rather than continue the relationship with Cleveland Clinic, True Health opted to perform its own MPO testing. In November 2015, Cleveland Clinic sued True Health, asserting infringement of the testing patents. Cleveland Clinic moved for a temporary restraining order and preliminary injunction, which the district court denied. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037655832&pubNum=0000999&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic Found. v. True Health Diagnostics, LLC
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, No. 1:15 CV 2331, 2015 WL 7430082, at *6 (N.D. Ohio Nov. 18, 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
After the district court denied the motion for temporary restraining order and preliminary injunction, Cleveland Clinic amended its complaint to add allegations of infringement of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f260 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. True Health moved to dismiss the amended complaint, arguing that the testing patents were directed to patent-ineligible subject matter and that Cleveland Clinic failed to state a claim for indirect infringement of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f260 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The district court granted True Health\u8217\'3fs motion. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038337569&pubNum=0000999&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic Found. v. True Health Diagnostics, LLC
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, No. 1:15 CV 2331, 2016 WL 705244, at *9 (N.D. Ohio Feb. 23, 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The district court found all the claims of the testing patents patent ineligible under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038337569&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at *5\u8211\'3f7
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The district court also dismissed the contributory and induced infringement claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f260 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and denied leave to amend the complaint. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038337569&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at *7\u8211\'3f9
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Procedurally, the district court found that it was proper to consider 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at the motion to dismiss stage. Although Cleveland Clinic argued that the district court should first conduct formal claim construction on some identified terms, the district court reasoned that \u8220\'3fplaintiff offer[ed] no proposed construction for these terms.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038337569&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at *3
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. And though Cleveland Clinic objected to treating any claims as representative of others, the district court found it appropriate to consider the above asserted claims representative because \u8220\'3fplaintiff fail[ed] to point out any claim that is not represented by the aforementioned claims.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038337569&pubNum=0000999&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The district court next found the testing patents patent ineligible under the two-step framework for analyzing patent subject matter eligibility under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 articulated in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice Corp. Pty. Ltd. v. CLS Bank Int\u8217\'3fl
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u8211\'3f\u8211\'3f\u8211\'3f U.S. \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f, 134 S.Ct. 2347, 2355, 189 L.Ed.2d 296 (2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038337569&pubNum=0000999&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2016 WL 705244, at *7
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The district court found that the testing patents\u8217\'3f claims were directed to a law of nature under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 step one because the claims were directed to \u8220\'3fthe correlation between MPO in the blood and the risk of [
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
].\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038337569&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at *6
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 step two, the district court found there was no saving inventive concept. First, the patents employ well-known methods to detect MPO. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038337569&pubNum=0000999&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Second, comparing MPO levels with a control value could be a bare mental process. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038337569&pubNum=0000999&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Finally, even looking at the claims as a whole, the steps in combination \u8220\'3fsimply instruct a user to apply a natural law, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, that an increase in MPO mass or MPO activity in a blood sample correlates 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1359_31}{\*\bkmkend co_pp_sp_506_1359_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1359
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to an increase in [
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
] risk.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038337569&pubNum=0000999&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Regarding infringement of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f260 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the district court found that True Health\u8217\'3fs testing service was not a \u8220\'3fmaterial or apparatus\u8221\'3f that could form the basis for contributory infringement. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038337569&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at *7\u8211\'3f8
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027859004&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1337&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1337" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
In re Bill of Lading Transmission & Processing Sys. Patent Litig.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 681 F.3d 1323, 1337 (Fed. Cir. 2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fContributory infringement occurs if a party sells or offers to sell, a material or apparatus for use in practicing a patented process, and that \u8216\'3fmaterial or apparatus\u8217\'3f is material to practicing the invention, has no substantial non-infringing uses, and is known by the party to be especially made or especially adapted for use in an infringement of such patent.\u8221\'3f) (internal quotation marks and citation omitted)).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Regarding induced infringement, the district court found that Cleveland Clinic did not allege facts sufficient to show the specific intent to induce a third party to infringe. The district court reasoned that, \u8220\'3fin generic terms, the third-party direct infringer must administer a lipid lowering agent based on elevated levels of MPO in order to infringe the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f260 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038337569&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at *9
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Hence, the \u8220\'3fplaintiff must sufficiently allege that defendant specifically intends to induce doctors to administer a lipid lowering agent based on elevated levels of MPO. The complaint is completely devoid of any factual allegations supporting this theory.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038337569&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
}}}
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In response to the motion to dismiss, Cleveland Clinic sought leave to amend its complaint in the event the claim was dismissed. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038337569&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The district court denied Cleveland Clinic\u8217\'3fs request. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038337569&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2004349872&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_699&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_699" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
PR Diamonds, Inc. v. Chandler
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 364 F.3d 671, 699 (6th Cir. 2004)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cleveland Clinic timely appealed. We have jurisdiction under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=28USCAS1295&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_7b9b000044381" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
28 U.S.C. \u167\'3f 1295(a)(1)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I6159be41c12a11eab3329bf22d04b}{\*\bkmkend co_anchor_I6159be41c12a11eab3329bf22d04b}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
Discussion
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We first address whether the testing patents are patent ineligible under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and conclude that they are. We next address whether the district court properly dismissed the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f260 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 infringement claims and conclude that it did.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I615a3371c12a11eab3329bf22d04b}{\*\bkmkend co_anchor_I615a3371c12a11eab3329bf22d04b}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
1. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
\sa200 
\sb400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
 Subject Matter Eligibility
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
A. Standard of Review
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B12041877586_31}{\*\bkmkend co_anchor_B12041877586_31}
}
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B22041877586_31}{\*\bkmkend co_anchor_B22041877586_31}
}
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B32041877586_31}{\*\bkmkend co_anchor_B32041877586_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
For procedural questions not unique to patent law, we review a grant of a motion to dismiss according to the law of the regional circuit, which in this case is the Sixth Circuit. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2031308890&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1319&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1319" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Univ. of Utah v. Max\u8211\'3fPlanck\u8211\'3fGesellschaft Zur Forderung Der Wissenschaften E.V.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 734 F.3d 1315, 1319 (Fed. Cir. 2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Sixth Circuit reviews de novo dismissals for failure to state a claim. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2001467177&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_360&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_360" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Bovee v. Coopers & Lybrand C.P.A.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 272 F.3d 356, 360 (6th Cir. 2001)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. We also review de novo whether a claim is patent-ineligible under the judicially created exceptions to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039786030&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1311&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1311" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
McRO, Inc. v. Bandai Namco Games Am. Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 837 F.3d 1299, 1311 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I615b6bf1c12a11eab3329bf22d04b}{\*\bkmkend co_anchor_I615b6bf1c12a11eab3329bf22d04b}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
B. Procedural Challenges
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
As a preliminary matter, we address Cleveland Clinic\u8217\'3fs procedural challenges to the district court\u8217\'3fs patentable subject matter eligibility analysis. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cleveland Clinic argues that the district court erred by analyzing only certain claims from each of the testing patents as representative. Cleveland Clinic also argues that the district court should have undertaken claim construction and developed the factual and expert record before analyzing whether the claims were eligible under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. We do not find these arguments persuasive.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B42041877586_31}{\*\bkmkend co_anchor_B42041877586_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
As to Cleveland Clinic\u8217\'3fs first procedural challenge, we find no error in the district court addressing claims 11, 14, and 15 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, claims 21 and 22 of 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1360_31}{\*\bkmkend co_pp_sp_506_1360_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1360
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2017572769&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=I86f818b8c15511ddbc7bf97f340af743&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f286 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and claim 5 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2029620427&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=Ib76976f05b5b11e2b7b9d48fe009f569&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f581 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 as representative. Although Cleveland Clinic argues that the unexamined dependent claims provide sufficient inventive concepts over the representative claims, our examination reveals the opposite. For example, Cleveland Clinic argues that the district court failed to take into consideration claims that require specific analytical techniques, claims that limit the predetermined comparison values to a single value or representative value or ranges, or claims that measure the presence of specific MPO-generated oxidation products. Each limitation Cleveland Clinic raises, however, merely recites known methods of detecting MPO or MPO derivatives and applies the correlation between these biomarkers and cardiovascular health. Where, as here, the claims \u8220\'3fare substantially similar and linked to the same\u8221\'3f law of nature, analyzing representative claims is proper. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035137097&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1348&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1348" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Content Extraction & Transmission LLC v. Wells Fargo Bank, N.A.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 776 F.3d 1343, 1348 (Fed. Cir. 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B52041877586_31}{\*\bkmkend co_anchor_B52041877586_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
As to Cleveland Clinic\u8217\'3fs second procedural challenge, we have repeatedly affirmed 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 rejections at the motion to dismiss stage, before claim construction or significant discovery has commenced. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038639328&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1373&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1373" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Genetic Techs. Ltd. v. Merial L.L.C.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 818 F.3d 1369, 1373\u8211\'3f74 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fWe have repeatedly recognized that in many cases it is possible and proper to determine patent eligibility under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 on a Rule 12(b)(6) motion.\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036435641&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1362&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1362" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
OIP Techs., Inc. v. Amazon.com, Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 788 F.3d 1359, 1362 (Fed. Cir. 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (similar); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035137097&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1349&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1349" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Content Extraction
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 776 F.3d at 1349
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (similar); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034265558&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1355" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
buySAFE, Inc. v. Google, Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 765 F.3d 1350, 1355 (Fed. Cir. 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (similar). In any event, Cleveland Clinic provided no proposed construction of any terms or proposed expert testimony that would change the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 analysis. Accordingly, it was appropriate for the district court to determine that the testing patents were ineligible under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at the motion to dismiss stage.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I615e5221c12a11eab3329bf22d04b}{\*\bkmkend co_anchor_I615e5221c12a11eab3329bf22d04b}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
C. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
\sa200 
\sb400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
 Step One
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of the Patent Act defines patent eligible subject matter:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Supreme Court has long held that there are certain exceptions to this provision: laws of nature, natural phenomena, and abstract ideas. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_708_2354&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2354" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S.Ct. at 2354
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (collecting cases).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B62041877586_31}{\*\bkmkend co_anchor_B62041877586_31}
}
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B72041877586_31}{\*\bkmkend co_anchor_B72041877586_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
To determine whether a claim is invalid under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, we employ the two-step 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 framework. In step one, we ask whether the claims are directed to ineligible subject matter, such as a law of nature. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S.Ct. at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_780_75&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_75" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo Collaborative Servs. v. Prometheus Labs., Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. 66, 75\u8211\'3f77, 132 S.Ct. 1289, 182 L.Ed.2d 321 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039786030&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1311&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1311" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
McRO
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 837 F.3d at 1311\u8211\'3f12
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1375&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1375" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa Diagnostics, Inc. v. Sequenom, Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 788 F.3d 1371, 1375 (Fed. Cir. 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. While method claims are generally eligible subject matter, method claims that are directed only to natural phenomena are directed to ineligible subject matter. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1376&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1376" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 788 F.3d at 1376
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. If the claims are directed to eligible subject matter, the inquiry ends. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041186463&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1349&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1349" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Thales Visionix Inc. v. United States
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 850 F.3d 1343, 1349 (Fed. Cir. 2017)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B82041877586_31}{\*\bkmkend co_anchor_B82041877586_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The claims of the testing patents are directed to multistep methods for observing the law of nature that MPO correlates to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
E.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, J.A. 50 at col. 30 ll. 47\u8211\'3f52; J.A. 71 at col. 24 ll. 11\u8211\'3f18; J.A. 86 at col. 20 ll. 12\u8211\'3f44. Moreover, the testing patents\u8217\'3f specifications similarly instruct that the inventions are 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1361_31}{\*\bkmkend co_pp_sp_506_1361_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1361
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8220\'3fbased on the discovery that patients with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 have significantly greater levels of leukocyte and [MPO],\u8221\'3f J.A. 36 at col. 2 ll. 33\u8211\'3f36; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 J.A. 67 at col. 16 ll. 56\u8211\'3f67 (describing the study\u8217\'3fs results as to MPO levels), 68 at col. 17 ll. 30\u8211\'3f39 (same), and they do not purport to alter MPO levels in any way, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038639328&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1376&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1376" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Genetic Technologies
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 818 F.3d at 1376
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (evaluating the asserted patents\u8217\'3f specification in support of its conclusion that the claims were focused on a patent-ineligible law of nature because, inter alia, they \u8220\'3finvolved[d] no creation or alteration of DNA sequences\u8221\'3f). Cleveland Clinic\u8217\'3fs invention thus involves \u8220\'3fseeing\u8221\'3f MPO already present in a bodily sample and correlating that to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Because the testing patents are based on \u8220\'3fthe relation [between 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and heightened MPO levels that] exists in principle apart from human action,\u8221\'3f they are directed to a patent-ineligible law of nature. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_780_77&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_77" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 77, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
This case is similar to our decision in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the ineligible claims were directed to a method of detecting paternally inherited cell-free fetal DNA, which is naturally occurring in maternal blood. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1376&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1376" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
788 F.3d at 1376
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The inventors there did not create or alter any of the genetic information encoded in that DNA. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Likewise, here, the testing patents purport to detect MPO and other MPO-related products, which are naturally occurring in bodily samples. The method then employs the natural relationship between those MPO values and predetermined or control values to predict a patient\u8217\'3fs risk of developing or having 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Thus, just like 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the method starts and ends with naturally occurring phenomena with no meaningful non-routine steps in between\u8212\'3fthe presence of MPO in a bodily sample is correlated to its relationship to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The claims are therefore directed to a natural law. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cleveland Clinic argues that its invention is similar to the patent-eligible invention described in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Rapid Litigation
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Management Ltd. v. CellzDirect, Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 827 F.3d 1042 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
CellzDirect
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the inventors developed cryo-preservation techniques to preserve liver cells for later use. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1045&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1045" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1045
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. We held that the claims were not directed to a natural law because they were \u8220\'3fsimply not directed to the ability of [liver cells] to survive multiple freeze-thaw cycles. Rather, the claims of the [asserted patent were] directed to a new and useful laboratory technique for preserving [liver cells].\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1048&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1048" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1048
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Unlike 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
CellzDirect
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the asserted claims of the testing patents are directed to the natural existence of MPO in a bodily sample and its correlation to cardiovascular risk rather than to \u8220\'3fa new and useful laboratory technique\u8221\'3f for detecting this relationship. Indeed, Cleveland Clinic has not created a new laboratory technique; rather, it uses well-known techniques to execute the claimed method. The specifications of the testing patents confirm that known testing methods could be used to detect MPO, and that there were commercially available testing kits for MPO detection. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
E.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, J.A. 39 at col. 8 ll. 32\u8211\'3f33; J.A. 38 at col. 6 ll. 21\u8211\'3f24.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Because the claims of the testing patents are directed to a natural law, we turn to the second step of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 framework.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I61646ca1c12a11eab3329bf22d04b}{\*\bkmkend co_anchor_I61646ca1c12a11eab3329bf22d04b}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
D. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
\sa200 
\sb400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
 Step Two
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B92041877586_31}{\*\bkmkend co_anchor_B92041877586_31}
}
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B102041877586_31}{\*\bkmkend co_anchor_B102041877586_31}
}
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B112041877586_31}{\*\bkmkend co_anchor_B112041877586_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 step two, we examine the elements of the claims to determine whether they contain an inventive concept sufficient to transform the claimed naturally occurring phenomena into a patent-eligible application. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_780_71&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_71" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 71\u8211\'3f72, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039786030&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1312&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1312" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
McRO
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 837 F.3d at 1312
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S.Ct. at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). We must consider the elements of the claims both individually and as an ordered combination 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1362_31}{\*\bkmkend co_pp_sp_506_1362_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1362
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to determine whether additional elements transform the nature of the claims into a patent-eligible concept. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1375&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1375" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 788 F.3d at 1375
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citations omitted). \u8220\'3fTo save a patent at step two, an inventive concept must be evident in the claims.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041531058&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1327&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1327" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
RecogniCorp, LLC v. Nintendo Co.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 855 F.3d 1322, 1327 (Fed. Cir. 2017)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B122041877586_31}{\*\bkmkend co_anchor_B122041877586_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We conclude that the practice of the method claims does not result in an inventive concept that transforms the natural phenomena of MPO being associated with cardiovascular risk into a patentable invention. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 make clear that transforming claims that are directed to a law of nature requires more than simply stating the law of nature while adding the words \u8220\'3fapply it.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_780_72&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_72" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 72, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1377&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1377" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 788 F.3d at 1377
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the challenged claims involved a method that was a general instruction to doctors to apply routine, conventional techniques when seeking to detect paternally inherited cell-free fetal DNA in the blood serum of a pregnant woman. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1377&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1377" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 788 F.3d at 1377
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The same is true here. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2029620427&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=Ib76976f05b5b11e2b7b9d48fe009f569&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f581 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 contain a \u8220\'3fdetermining\u8221\'3f step that requires analyzing MPO levels. Cleveland Clinic does not purport to have invented colorimetric-based assay, flow 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic8ad5894475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cytometry
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, or ELISA, or any of the claimed methods to \u8220\'3fsee\u8221\'3f MPO and its derivatives in bodily samples. Rather, the claims here instruct that MPO levels be detected or determined using any of these known techniques. The claims of the testing patents also contain a \u8220\'3fcomparing\u8221\'3f step where MPO levels are compared to statistically derived control or predetermined values. Here too, Cleveland Clinic does not purport to derive new statistical methods to arrive at the predetermined or control levels of MPO that would indicate a patient\u8217\'3fs risk of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Known statistical models can be employed, as described, for example, in the specification of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f552 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
Predetermined values of MPO activity or MPO mass, such as for example, mean levels, median levels, or \u8220\'3fcut-off\u8221\'3f levels, are established by assaying a large sample of individuals in the general population or the select population and using a statistical model such as the predictive value method for selecting a positivity criterion or receiver operator characteristic curve that defines optimum specificity (highest true negative rate) and sensitivity (highest true positive rate) as described in Knapp, R.G., and Miller, M.C. (1992)....
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
J.A. 46 at col. 21 ll. 12\u8211\'3f20.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The claims, whether considered limitation-by-limitation or as a whole, do not sufficiently transform the natural existence of MPO in a bodily sample and its correlation to cardiovascular risk into a patentable invention. The process steps here merely tell those \u8220\'3finterested in the subject about the correlations that the researchers discovered.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_780_78&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_78" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 78, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cleveland Clinic\u8217\'3fs invention here is distinct from the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
CellzDirect
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 invention when examining 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 step two. In 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
CellzDirect
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the inventors took the discovery that certain liver cells will survive multiple freeze-thaw cycles and applied that to improve existing methods for preserving liver cells. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1051&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1051" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
CellzDirect
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 827 F.3d at 1051
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Here, the testing patents here do not extend their discovery that MPO correlates to cardiovascular risk to a patentable method. They require only conventional MPO detection methods and compare those values to predetermined or control values derived from conventional statistical methods.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00022041877586_ID0EEMBI_31}{\*\bkmkend co_fnRef_B00022041877586_ID0EEMBI_31}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00022041877586_31" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
2
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1363_31}{\*\bkmkend co_pp_sp_506_1363_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1363
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B132041877586_31}{\*\bkmkend co_anchor_B132041877586_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cleveland Clinic argues that its invention is narrowly preemptive and thus should be patent eligible. However, \u8220\'3f[w]here a patent\u8217\'3fs claims are deemed only to disclose patent ineligible subject matter under the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 framework, as they are in this case, preemption concerns are fully addressed and made moot.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1379&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1379" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 788 F.3d at 1379
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Likewise, while Cleveland Clinic argues that its discovery of the relationship between MPO and cardiovascular health was groundbreaking, \u8220\'3feven such valuable contributions can fall short of statutory patentable subject matter, as it does here.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036438466&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1380&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1380" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1380
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Accordingly, we affirm the district court\u8217\'3fs determination that the testing patents are directed to patent-ineligible subject matter.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I617164f1c12a11eab3329bf22d04b}{\*\bkmkend co_anchor_I617164f1c12a11eab3329bf22d04b}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
2. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f260 Patent
}}}
\sa200 
\sb400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
 Infringement
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f260 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is a method-of-treatment patent whose claims require \u8220\'3fadministering a lipid lowering agent to the selected human patient.\u8221\'3f J.A. 117 at col. 30 ll. 22\u8211\'3f24. Cleveland Clinic does not allege that True Health directly infringes this patent, rather, it alleges that True Health indirectly infringes via contributory and induced infringement. As discussed below, we find that the district court properly dismissed Cleveland Clinic\u8217\'3fs claims.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I617312a1c12a11eab3329bf22d04b}{\*\bkmkend co_anchor_I617312a1c12a11eab3329bf22d04b}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
A. Standard of Review
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B142041877586_31}{\*\bkmkend co_anchor_B142041877586_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In the Sixth Circuit, courts employ two standards of review for denials of motions to amend complaints: (1) abuse of discretion, the general standard when a court denies a motion for leave to amend; or (2) de novo, the standard when a court denies leave to amend because the amended pleading would not withstand a motion to dismiss. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2025804200&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_304&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_304" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Pulte Homes, Inc. v. Laborers\u8217\'3f Int\u8217\'3fl Union of N. Am.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 648 F.3d 295, 304\u8211\'3f05 (6th Cir. 2011)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citations omitted). Here, like in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2025804200&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Pulte
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Cleveland Clinic did not file a motion for leave to amend, but rather \u8220\'3fburied its request ... in its brief opposing the motion to dismiss\u8221\'3f and the district court \u8220\'3fdid not explain why it withheld leave to amend. The lesser standard, abuse of discretion, therefore applies.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2025804200&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_305&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_305" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 305
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I61750e71c12a11eab3329bf22d04b}{\*\bkmkend co_anchor_I61750e71c12a11eab3329bf22d04b}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
B. The District Court Properly Dismissed Cleveland Clinic\u8217\'3fs Contributory Infringement Claims
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B152041877586_31}{\*\bkmkend co_anchor_B152041877586_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Contributory infringement occurs if a party sells, or offers to sell, a material or apparatus for use in practicing a patented process, and that \u8220\'3fmaterial or apparatus\u8221\'3f is material to practicing the invention, it has no substantial non-infringing uses, and it is known by the party \u8220\'3fto be especially made or especially adapted for use in an infringement of such patent.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_4b24000003ba5" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027859004&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1337&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1337" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Bill of Lading
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 681 F.3d at 1337
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. A party that provides a service, but no \u8220\'3fmaterial or apparatus,\u8221\'3f cannot be liable for contributory infringement. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012652319&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1357&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1357" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
PharmaStem Therapeutics, Inc. v. ViaCell, Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 491 F.3d 1342, 1357 (Fed. Cir. 2007)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fUnder the plain language of the statute, a person who provides a service that assists another in committing patent infringement may be subject to liability under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_a83b000018c76" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(b)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 for active inducement of infringement, but not under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_4b24000003ba5" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 for contributory infringement.\u8221\'3f
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B162041877586_31}{\*\bkmkend co_anchor_B162041877586_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
True Health provides MPO testing services. The only \u8220\'3fmaterial or apparatus\u8221\'3f that Cleveland Clinic claims True Health sells are lab reports documenting the results of True Health\u8217\'3fs testing services. We agree with the district court that the \u8220\'3flab reports attached to the complaint reflect the manner in which defendant reports the results of the service it provides.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038337569&pubNum=0000999&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2016 WL 705244, at *8
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. They are not a \u8220\'3fmaterial or apparatus.\u8221\'3f Accordingly, it was not an abuse of 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1364_31}{\*\bkmkend co_pp_sp_506_1364_31}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1364
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 discretion for the district court to dismiss Cleveland Clinic\u8217\'3fs contributory infringement claims and deny leave to amend.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I61781bb1c12a11eab3329bf22d04b}{\*\bkmkend co_anchor_I61781bb1c12a11eab3329bf22d04b}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
C. The District Court Properly Dismissed Cleveland Clinic\u8217\'3fs Induced Infringement Claims
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B172041877586_31}{\*\bkmkend co_anchor_B172041877586_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8220\'3fWhoever actively induces infringement of a patent shall be liable as an infringer.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_a83b000018c76" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(b)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fHowever, knowledge of the acts alleged to constitute infringement is not enough.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2010878868&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&fi=co_pp_sp_506_1305&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1305" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
DSU Med. Corp. v. JMS Co.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 471 F.3d 1293, 1305 (Fed. Cir. 2006)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (en banc) (citations omitted). The mere knowledge of possible infringement by others does not amount to inducement; specific intent and action to induce infringement must be proven. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2010878868&pubNum=0000506&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf20 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B182041877586_31}{\*\bkmkend co_anchor_B182041877586_31}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
It is undisputed that True Health does not sell or prescribe lipid lowering drugs to patients. Cleveland Clinic argues that True Health\u8217\'3fs lab reports are sufficient to create the reasonable inference that a doctor who ordered such a report would rely on the results and would administer a lipid lowering agent where the results indicated the patient had a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 risk. Cleveland Clinic alleges no facts that suggest any connection between True Health and doctors that may prescribe lipid lowering drugs. Cleveland Clinic thus falls short of showing \u8220\'3fspecific intent and action\u8221\'3f on behalf of True Health to induce infringement of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f260 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. It was not an abuse of discretion for the district court to dismiss Cleveland Clinic\u8217\'3fs induced infringement claims and deny leave to amend.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I617a1781c12a11eab3329bf22d04b}{\*\bkmkend co_anchor_I617a1781c12a11eab3329bf22d04b}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
Conclusion
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We have considered Cleveland Clinic\u8217\'3fs other arguments and do not find them persuasive. We thus affirm the district court\u8217\'3fs grant of True Health\u8217\'3fs motion to dismiss.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
AFFIRMED
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_allCitations_31}{\*\bkmkend co_allCitations_31}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
All Citations
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
859 F.3d 1352, 123 U.S.P.Q.2d 1081
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \ltrrow \trleft0 
\clpadl200 \clpadfl3 \clbrdrt \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf1 \f4 \i0 \fs20 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Footnotes
\par 
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \ql \li0 \fs20 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00012041877586_31}{\*\bkmkend co_footnote_B00012041877586_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00012041877586_ID0ER2AG_31" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
1
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The testing patents are 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
U.S. Patent No. 7,223,552
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2017572769&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=I86f818b8c15511ddbc7bf97f340af743&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
U.S. Patent No. 7,459,286
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2029620427&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=Ib76976f05b5b11e2b7b9d48fe009f569&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
U.S. Patent No. 8,349,581
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
. The fourth patent, which relates to a method for treating a patient, is 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
U.S. Patent No. 9,170,260
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2012354687&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=If5d6f9a50e3e11dcb92c924f6a2d2928&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f552 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f260 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 share a specification, as do the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2017572769&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=I86f818b8c15511ddbc7bf97f340af743&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f286 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2029620427&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=Ib76976f05b5b11e2b7b9d48fe009f569&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f581 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrb \clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00022041877586_31}{\*\bkmkend co_footnote_B00022041877586_31}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00022041877586_ID0EEMBI_31" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
2
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2037478806&pubNum=0004074&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=PA&docFamilyGuid=I9155a0507e8b11e5b9cec03b9e323c7d&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u8217\'3f260 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, which claims a method of treating a patient that is determined to have a risk of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
cardiovascular disease
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, is not challenged under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=Ic994c70052ad11e7a3f3a229dca6c9c6&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f4 \i0 \fs18 \chcbpat23 
{\b1 \cf22 \f4 \i0 \fs18 \chcbpat23 
{\b1 \cf22 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f
}
}
}
{\b0 \cf20 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf22 \f4 \i0 \fs18 \chcbpat23 
{\b1 \cf22 \f4 \i0 \fs18 \chcbpat23 
{\b1 \cf22 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf20 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \lastrow \trleft0 
\clpadt24 \clpadft3 \clpadl100 \clpadfl3 \clpadr24 \clpadfr3 \clbrdrt \brdrcf27 \brdrw10 \brdrs \clbrdrb \clbrdrl \trql \clvertalt \clwWidth4320 \cellx4320 
\clpadt29 \clpadft3 \clpadl100 \clpadfl3 \clpadr29 \clpadfr3 \clbrdrt \brdrcf27 \brdrw10 \brdrs \clbrdrb \clbrdrr \trql \clvertalt \clwWidth5760 \cellx10080 
\intbl 
{\ri24 \li24 
{\b1 \cf27 \f4 \ri24 \i0 \ql \fs16 \li24 
{\b1 \cf27 \f4 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
End of Document
\par 
}
}
}\b1 \cf27 \f4 \ri24 \ul0 \strike0 \i0 \ql \li24 \fs16 \sa0 \sb0 \intbl \cell \intbl 
{\ri29 \li29 
{\qr \b0 \cf27 \f4 \ri29 \i0 \fs19 \li29 
{\b0 \cf27 \f4 \ul0 \strike0 \i0 \fs19 \sa0 \sb0 
\u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
\par 
}
}
}\qr \b0 \cf27 \f4 \ri29 \ul0 \strike0 \i0 \li29 \fs19 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}\sect }